Collection

Early access to medicines scheme (EAMS): scientific opinions

From:
Medicines and Healthcare products Regulatory Agency
Published:
3 June 2015
Last updated:
1 September 2017, see all updates

Information on granted EAMS scientific opinions, including the public assessment report and treatment protocols.

See expired scientific opinions.

Current EAMS

  1. Early access to medicines scheme (EAMS) scientific opinion: Alectinib as monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)

    • Decision

  2. Early access to medicines scheme (EAMS) scientific opinion: Raxone to treat the decline of respiratory function in patients with Duchenne Muscular Dystrophy

    • Decision

  3. Early access to medicines scheme (EAMS) scientific opinion: Dupilumab for treatment of dermatitis

    • Decision
Contents

Document information

Published: 3 June 2015

Updated: 1 September 2017

+ full page history

  1. Link to the EAMS Scientific Opinion for Alectinib has been added to the page.
  2. New EAMS scientific opinion for Raxone added to the collections page.
  3. New EAMS scientific opinion for Oxervate added to the page.
  4. Added EAMS scientific opinion: Glecaprevir/Pibrentasvir for the treatment of chronic hepatitis C (HCV) infection in adults
  5. EAMS for Dupilumab published
  6. SO for pembrolizumab for non-small cell lung cancer removed from current EAMS list.
  7. New EAMS positive scientific opinion
  8. Nivolumab to treat a type of cancer of the Lymph system - the Scientific Opinion has now expired due to a positive EC decision
  9. Added link to the scientific opinion: venetoclax for the treatment of chronic lymphocytic leukaemia (CLL)
  10. Added: Early access to medicines scheme (EAMS) scientific opinion: osimertinib (AZD9291) 40 and 80mg film-coated tablets
  11. New EAM issued to Novartis for sacubitril-valsartan
  12. First published.

From: Medicines and Healthcare products Regulatory Agency